Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

14 janv. 2026 18h00 HE | Source: Belo Sun Mining Corp.

Belo Sun Receives Ruling From Federal Court of Altamira, Para

TORONTO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX: BSX; OTCQB:BSXGF) announces that the Federal Court of Altamira, Pará, Brazil, denied the...
09 janv. 2026 20h06 HE | Source: Etienna Bio, Inc.

Etienna Bio Secures Exclusive Worldwide License from UMass Chan Medical School for Novel Adipose-Derived Regenerative Platform

Etienna Bio signs license agreement with UMass Chan Medical Center
09 janv. 2026 08h30 HE | Source: Perma-Fix Environmental Services, Inc

Perma-Fix Environmental Services Receives Expanded Permit for Richland Facility, Approximately Tripling Liquid Mixed Waste Processing Capacity

ATLANTA, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced that it has received a final Dangerous Mixed Waste Permit Renewal for...
09 janv. 2026 08h00 HE | Source: Medicines360

Medicines360 Acquires Global Licensing Rights to Innovative Maternal Health Technologies for Risk Identification and Management Throughout Pregnancy

Licensing of scientific discoveries from University of Cambridge and University of Edinburgh is aimed to speed translation and access to life-saving diagnostics for women worldwide. SAN FRANCISCO,...
09 janv. 2026 08h00 HE | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra® (resmetirom) for...
09 janv. 2026 07h05 HE | Source: uniQure Inc.

uniQure Announces Type A Meeting Scheduled with FDA

LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
08 janv. 2026 02h48 HE | Source: Nxera Pharma

Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

Vamorolone is approved and marketed as AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD) in the US, European Union, UK and ChinaNew five-year data on vamorolone highlighted substantially...
05 janv. 2026 20h00 HE | Source: Biogen Inc.

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China

TOKYO and CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...
05 janv. 2026 16h01 HE | Source: Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression

Cyclerion & Medsteer entered a strategic agreement to enable the integration of Medsteer's technology and know-how into CYC-126.
05 janv. 2026 07h00 HE | Source: Skye Bioscience, Inc.

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Skye Bioscience, Inc. (Nasdaq: SKYE) today announced the companies entered into a non-exclusive global...

Page précédente

Page suivante